Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

Insulin, chemotherapy, and the mechanisms of malignancy: the design and the demise of cancer.

Ayre SG, Garcia y Bellon DP, Garcia DP Jr.

Med Hypotheses. 2000 Oct;55(4):330-4.

PMID:
11000062
[PubMed - indexed for MEDLINE]
2.

A new classification system of anticancer drugs - based on cell biological mechanisms.

Wu XZ.

Med Hypotheses. 2006;66(5):883-7. Epub 2006 Jan 18.

PMID:
16414204
[PubMed - indexed for MEDLINE]
3.

Energy balance, physical activity, and cancer risk.

Fair AM, Montgomery K.

Methods Mol Biol. 2009;472:57-88. doi: 10.1007/978-1-60327-492-0_3. Review.

PMID:
19107429
[PubMed - indexed for MEDLINE]
4.

Novel cytotoxic drugs: old challenges, new solutions.

Ismael GF, Rosa DD, Mano MS, Awada A.

Cancer Treat Rev. 2008 Feb;34(1):81-91. Epub 2007 Oct 1. Review.

PMID:
17905518
[PubMed - indexed for MEDLINE]
5.

Modulation of chemotherapy antineoplastic agents with biologic agents: enhancement of antitumor activities by interleukin-1.

Johnson CS.

Curr Opin Oncol. 1992 Dec;4(6):1108-15. Review.

PMID:
1457525
[PubMed - indexed for MEDLINE]
6.

Rationales for combining chemotherapy and biotherapy in the treatment of cancer.

Dillman RO.

Mol Biother. 1990 Dec;2(4):201-7. Review.

PMID:
2288719
[PubMed - indexed for MEDLINE]
7.

Combinatorial application of nucleic acid-based agents targeting protein kinases for cancer treatment.

Spänkuch B, Strebhardt K.

Curr Pharm Des. 2008;14(11):1098-112. Review.

PMID:
18473857
[PubMed - indexed for MEDLINE]
8.

Tamoxifen modulation of etoposide cytotoxicity involves inhibition of protein kinase C activity and insulin-like growth factor II expression in brain tumor cells.

Ramachandran C, Khatib Z, Petkarou A, Fort J, Fonseca HB, Melnick SJ, Escalon E.

J Neurooncol. 2004 Mar-Apr;67(1-2):19-28.

PMID:
15072444
[PubMed - indexed for MEDLINE]
9.

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.

Baxevanis CN, Perez SA, Papamichail M.

Cancer Immunol Immunother. 2009 Mar;58(3):317-24. doi: 10.1007/s00262-008-0576-4. Epub 2008 Aug 15. Review.

PMID:
18704409
[PubMed - indexed for MEDLINE]
10.

The metal-binding domain of IGFBP-3 selectively delivers therapeutic molecules into cancer cells.

Huq A, Singh B, Meeker T, Mascarenhas D.

Anticancer Drugs. 2009 Jan;20(1):21-31. doi: 10.1097/CAD.0b013e3283144610.

PMID:
19342998
[PubMed - indexed for MEDLINE]
11.

Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models.

Alami N, Page V, Yu Q, Jerome L, Paterson J, Shiry L, Leyland-Jones B.

Growth Horm IGF Res. 2008 Dec;18(6):487-96. doi: 10.1016/j.ghir.2008.04.002. Epub 2008 May 23.

PMID:
18502161
[PubMed - indexed for MEDLINE]
12.
13.

Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy.

Fisher M, Yang LX.

Anticancer Res. 2002 May-Jun;22(3):1737-54. Review.

PMID:
12168863
[PubMed - indexed for MEDLINE]
14.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
[PubMed - indexed for MEDLINE]
15.

Cytotoxicity and immunostimulation: double attack on cancer cells with polymeric therapeutics.

Ríhová B, Kovár L, Kovár M, Hovorka O.

Trends Biotechnol. 2009 Jan;27(1):11-7. doi: 10.1016/j.tibtech.2008.10.006. Epub 2008 Nov 18.

PMID:
19022512
[PubMed - indexed for MEDLINE]
16.

Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.

Shah MA, Schwartz GK.

Clin Cancer Res. 2001 Aug;7(8):2168-81. Review.

PMID:
11489790
[PubMed - indexed for MEDLINE]
Free Article
17.

Ultrasound assistant chemotherapy may be a novel modality for solid tumors.

Pan H, Ma X, Li M, Chen J, Jiang H.

Med Hypotheses. 2009 Oct;73(4):526-7. doi: 10.1016/j.mehy.2009.06.007. Epub 2009 Jul 1.

PMID:
19573996
[PubMed - indexed for MEDLINE]
18.

The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.

Workman P.

Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S45-56. Epub 2003 Jun 18. Review.

PMID:
12819933
[PubMed - indexed for MEDLINE]
19.

Chemotherapy may be delivered based on an integrated view of tumour dynamics.

Ribba B, You B, Tod M, Girard P, Tranchand B, Trillet-Lenoir V, Freyer G.

IET Syst Biol. 2009 May;3(3):180-90. doi: 10.1049/iet-syb.2008.0104.

PMID:
19449978
[PubMed - indexed for MEDLINE]
20.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk